+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Hidradenitis Suppurativa Market Size was valued at USD 0.7 Billion in 2022. The Hidradenitis Suppurativa market industry is projected to grow from USD 0.8 Billion in 2023 to USD 0.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.50% during the forecast period (2023 - 2032). Rising rates of obesity, increased funding for healthcare infrastructure, increased awareness-raising efforts by both public and private organizations, and an increase in the prevalence of skin diseases are all significant causes, are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The market for hidradenitis suppurativa is anticipated to flourish with rising prevalence of several skin ailments over the current forecast period, which will finish in 2028. The FDA is authorizing medicine and clinical trial processes, which is aiding in the development and growth of the global market for hidradenitis suppurativa. Along with a growth in knowledge about skin disorders and other healthcare difficulties, new trends in medicine and therapy are also expected to spur market expansion. The increasing level of global warming in every region of the planet has exacerbated global environmental problems like pollution and ozone layer depletion. Additionally, the skin of the target market is being adversely affected globally, which is fueling the growth of the hidradenitis suppurativa market throughout the course of the evaluation period of 2017–2023.
The market for hidradenitis suppurativa is growing, and its growth rate is significantly impacted by the rising cost of healthcare. The market for hidradenitis suppurativa will expand as a result of rising public and private organization awareness-raising initiatives as well as a rise in the prevalence of obesity. Additionally, as a result of rising disposable income and people's changing lifestyles, the market for hidradenitis suppurativa will expand. Along with this, the market's growth will be accelerated by an aging population and rising smoking rates.
The rise in the prevalence of skin diseases is also one of the major drivers of market expansion (UI). The hidradenitis suppurativa market is also being driven by secondary infections, hair follicle blockages, and irritation of particular sweat glands. Thus, driving the Hidradenitis Suppurativa market revenue.
The global Hidradenitis Suppurativa market segmentation, based on Skin Conditions includes Pimples, Folliculitis, Deep-acne like cysts & blackheads, and Boils. The market was dominated by the deep-acne like cysts and blackheads category, which generated 29% of market revenue (0.09 billion). EGF is a very powerful acne treatment, especially when used in place of harsher drugs like retinol, which also accelerate cellular turnover.
The global Hidradenitis Suppurativa market segmentation, based on treatment, includes Medications and Surgery. The category of pharmaceuticals produced the largest revenue (68.4%). Treatment for Hidradenitis Suppurativa (HS) may involve the use of antibiotics, biologics, retinoids, corticosteroids, and hormone treatment, among other medications.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. The North America Hidradenitis Suppurativa Market dominated this market in 2022 (45.80%). The prevalence of HS varies between 0.1% and 2% in North America, with a preference for people in their third and fourth decades of life. Although the exact cause of HS is unknown, genetic and environmental factors are known to contribute to the disorder. The disease's primary symptom is a blockage of the hair follicles, which can cause nodules, abscesses, and skin tunnels to form. Further, In the North American area, the U.S. Hidradenitis Suppurativa market had the biggest market share, while the Canada Hidradenitis Suppurativa market had the quickest rate of expansion.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Europe Hidradenitis Suppurativa market accounts for the second-largest market share. This is due to the fact that the European S1 guideline recommends medicinal therapy for the treatment of HS, which may include antibiotics, acitretin, and biologics like adalimumab and infliximab. Further, In the European region, the German Hidradenitis Suppurativa market had the biggest market share, and the U.K. Hidradenitis Suppurativa market had the quickest rate of growth.
The Asia-Pacific Hidradenitis Suppurativa Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to an increase in inflammatory skin illnesses, rising healthcare awareness and government backing, an increase in generic drug producers, and an increase in government initiatives in this field. Moreover, In the Asia-Pacific region, the Indian Hidradenitis Suppurativa market had the quickest rate of growth while China's Hidradenitis Suppurativa market had the greatest market share.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Hidradenitis Suppurativa market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Hidradenitis Suppurativa sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Hidradenitis Suppurativa industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Hidradenitis Suppurativa sector. Major players in the Hidradenitis Suppurativa market, including AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US) and others, are attempting to increase market demand by investing in research and development operations.
The international pharmaceutical and biotechnology corporation Pfizer was founded in 1849 in New York by two German businessmen, Charles Pfizer and Charles F. Erhart. The company's headquarters are in Manhattan, New York City. Leading biopharmaceutical company Pfizer places a big emphasis on research. Medication that helps people live longer, significantly better lives is created using research and worldwide resources. The company's global portfolio includes a number of well-known consumer healthcare products, vaccines, and medications. The commitment of Pfizer to ESG encompasses a wide range of topics, including product innovation, equitable access to and price of products, product quality and safety, diversity, fairness, and inclusion, and climate change. The company has bought a number of companies, including Amplyx Pharmaceuticals and the maker of the antifungal medication fosmanogepix. In addition, Pfizer was hit with a $3 billion fine as a result of jury verdicts, civil penalties, and criminal convictions for deceptive marketing tactics, doctor kickbacks, and concealing poor trial results.
AstraZeneca is a global, science-based biopharmaceutical firm that develops, manufactures, and markets pharmaceuticals and biotechnology for the treatment of disorders of the respiratory, digestive, cardiovascular, and oncological systems. Modern pharmaceuticals produced by the firm are used by millions of people worldwide. AstraZeneca's purpose and values call for adherence to research and patient priority. The company has a portfolio of therapeutics for important diseases in addition to leading an oncology revolution to rethink cancer care for the millions of people living with cancer. The business is still waiting for FDA approval to use the vaccine in an emergency in the US.
· AstraZeneca (UK)
· Pfizer Inc.(US)
· GlaxoSmithKline plc. (UK)
· Merck & Co., Inc. (US)
· Johnson & Johnson Services, Inc. (US)
June 2022: Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus were published by vRoivant and Pfizer.
March 2022: MoonLake Immunotherapeutics has started an international Phase II clinical trial using the investigational nanobody sonelokimab to treat moderate-to-severe hidradenitis suppurativa (HS).
February 2021: AbbVie Inc. received FDA approval for HUMIRA (adalimumab), a medication that can be used to treat mild to severe hidradenitis suppurativa.
· Pimples
· Folliculitis
· Deep-acne like cysts and blackheads
· Boils
· Medications
· Surgery
· North America
- U.S.
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 0.7 Billion |
|
Market Size 2023 |
USD 0.8 Billion |
|
Market Size 2032 |
USD 0.9 Billion |
|
Compound Annual Growth Rate (CAGR) |
5.50% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Skin Conditions, Treatment, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
AstraZeneca (UK), Pfizer Inc.(US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), Others |
|
Key Market Opportunities |
Technological advancement and increase in the number of research and development activities |
|
Key Market Dynamics |
Rise in inflammatory skin disease, healthcare awareness, and government support, |
The global Hidradenitis Suppurativa Market was valued at USD 0.7 billion in 2022, and it is estimated to reach USD 0.9 billion by 2032.
The global market is projected to grow at a CAGR of 5.50% during the forecast period, 2023-2032.
Asia Pacific had the largest share in the global market
The key players in the market are AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), Others.
The deep-acne like cysts and blackheads category dominated the market in 2022.
The medications had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65261
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst